# Can Mert

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/can-mert/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68 |
| Field | Inflammatory Bowel Disease |
| h-index | 4 |
| i10-index | 3 |
| OpenAlex ID | https://openalex.org/A5046072430 |
| Works | 10 |

## Researcher papers

- [Factors Predicting Quality of Life Impairment in Adult Patients with Atopic Dermatitis: Results from a Patient Survey and Machine Learning Analysis](https://scholariq.org/papers/factors-predicting-quality-of-life-impairment-in-adult-patients-with-atopic/)
- [Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey](https://scholariq.org/papers/real-world-treatment-patterns-and-treatment-benefits-among-adult-patients-with/)
- [Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain](https://scholariq.org/papers/real-world-treatment-patterns-resource-use-and-costs-in-adult-patients-with/)
- [\[Artículo traducido\] Características de los pacientes, patrones de tratamiento, uso de recursos y costes en adultos con dermatitis atópica moderada-grave en la práctica habitual en España: Estudio Derma-Atopic](https://scholariq.org/papers/articulo-traducido-caracteristicas-de-los-pacientes-patrones-de-tratamiento-uso/)
- [Dose Escalation Patterns and Associated Costs of Advanced Therapies for Ulcerative Colitis in France and the United Kingdom: A Retrospective Database Analysis](https://scholariq.org/papers/dose-escalation-patterns-and-associated-costs-of-advanced-therapies-for/)
- [P912 A Real-World Evidence Study of Dose Escalation and associated costs of advanced therapies for Ulcerative Colitis in France and United Kingdom](https://scholariq.org/papers/p912-a-real-world-evidence-study-of-dose-escalation-and-associated-costs-of/)
- [P94 Real-world evidence study of dose escalation and associated costs of advanced therapies for ulcerative colitis in France and United Kingdom](https://scholariq.org/papers/p94-real-world-evidence-study-of-dose-escalation-and-associated-costs-of/)
- [S1305 TNFi Cyclers vs MOA Switchers in a Real-World Population of TNFi-Experienced Patients With Ulcerative Colitis: A Propensity Score Adjusted Analysis](https://scholariq.org/papers/s1305-tnfi-cyclers-vs-moa-switchers-in-a-real-world-population-of-tnfi/)
- [MSR217 Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease](https://scholariq.org/papers/msr217-using-propensity-weighting-methods-with-real-world-data-and-noncontrolled/)
- [Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi](https://scholariq.org/papers/real-world-outcomes-of-tumour-necrosis-factor-inhibitor-tnfi-cyclers-versus/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.